Physician profile
Emily Jih
NPI 1376114231
$2,072.18
in general payments reported to CMS, 2019-2025
29 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $450 · 2023: $561 · 2024: $717 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.61 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $116.02 | 2023-2024 | Ocaliva |
| Sobi, INC | $108.11 | 2024-2025 | |
| Incyte Corporation | $99.06 | 2024-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $90.52 | 2023-2024 | Zeposia, Reblozyl |
| Pharmaessentia USA Corporation | $87.87 | 2024-2025 | Besremi |
| Merck Sharp & Dohme LLC | $87.05 | 2022-2025 | Welireg, Keytruda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.12 | 2022-2023 | Trulance |
| Lilly USA, LLC | $61.24 | 2024 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $53.25 | 2022-2023 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $50.55 | 2024-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals Lp | $50.26 | 2024 | Calquence, Imfinzi |
| Glaxosmithkline, LLC. | $46.35 | 2025 | Ojjaara |
| Genzyme Corporation | $43.49 | 2022 | |
| Gilead Sciences, INC. | $40.83 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $37.43 | 2022-2023 | Sutab |
| Stemline Therapeutics INC. | $35.53 | 2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $34.96 | 2024 | Tazverik |
| Rigel Pharmaceuticals, INC. | $33.43 | 2024 | Rezlidhia, Tavalisse |
| Pfizer INC. | $30.96 | 2023 | |
| Tersera Therapeutics LLC | $28.10 | 2025 | Zoladex |
| Phathom Pharmaceuticals, INC. | $26.94 | 2024 | Voquezna |
| Kyowa Kirin, INC. | $25.06 | 2025 | |
| Emd Serono, INC. | $23.58 | 2025 | |
| Exelixis INC. | $22.91 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $22.60 | 2024 | Darzalex |
| Alexion Pharmaceuticals, INC. | $22.28 | 2022 | |
| Redhill Biopharma INC. | $14.81 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.26 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Jih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.